Afm13 clinical trial

Author: vlfa

August undefined, 2024

WebDec 10, 2024 · December 10, 2024, 2:20 PM · 9 min read Affimed N.V. AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin... WebAug 30, 2024 · Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin …

Ozmosi Drug Profile - AFM-13

WebGiving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer growth in patients with CD30 positive AFM13-NK Hodgkin and Non … WebThe purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. Participation eligibility Participant eligibility … thorne industrial estate

phase 1b study of AFM13 in combination with …

WebJul 1, 2024 · AFM13-NK complex cells exhibited enhanced responses to CD30+lymphomas in vitroand in vivo. Conclusions: We identify AFM13 as a promising combination with … WebApr 10, 2024 · Affimed’s AFM13 is a proprietary bispecific antibody designed to bind to CD16A on NK cells and CD30 on lymphoma cells, allowing NK cells to eliminate cancer … WebDec 10, 2024 · AFM13 is a first-in-class innate cell engager (ICE ®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. umpf meaning

phase 1 study of the bispecific anti-CD30/CD16A antibody …

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 …

WebClinical Trials / AFM13 in Relapsed/Refractory Cutaneous Lymphomas. NCT03192202. Description: The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma. ... WebSearch clinical trials for: AFM13 . Total 5 results. NCT04074746. Recruiting. Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas. ump fee scheduleWebApr 14, 2024 · American Association for Cancer Research (AACR) 2024 Preview – Top Data Readouts. The upcoming AACR 2024 Annual Meeting will have a range of abstracts, including regular abstracts, clinical trials, and late-breaking abstracts. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we … thorne in spanish

"WebJan 28, 2016 · Brief Summary: The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy. Condition or disease. " - Afm13 clinical trial

Afm13 clinical trial

A phase 2 study of AFM13, a bispecific cell engager targeting …

WebResearchers at Columbia University are carrying out an open-label Phase 1/2 clinical trial ( NCT03192202) assessing AFM13 as a therapy for CTCL in an estimated 18 patients. Other information AFM13 was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in September 2009. *** WebTo assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A-C), we initiated a randomized two-stage phase II trial ( NCT02321592 ). Due to slow recruitment, the trial was terminated after treatment of 25 patients.

Did you know?

WebMar 11, 2024 · In a presentation at the 2024 American Society of Hematology Annual Meeting, AFM13 monotherapy demonstrated a response rate of 42% in 14 patients with CD30-positive lymphomas treated on a phase 1b/2 trial (NCT03192202). Circulating NK cells decreased during therapy, as made evident by flow cytometry monitoring.

WebAFM13 in clinical trials A completed Phase 1 study ( NCT01221571) assessed the safety, tolerability, and activity of AFM13 in 28 patients with HL that returned despite treatment … WebGHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma Conditions: Hodgkin Lymphoma …

WebAug 1, 2015 · Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK … WebJan 6, 2024 · REDIRECT, also known as AFM13-202 (NCT04101331), is a registration-directed phase 2 open-label, multicenter, global study investigating the efficacy and safety of AFM13 monotherapy in patients...

WebSep 24, 2024 · This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma. The …

WebDec 22, 2014 · GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (GHSG-AFM13) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. umphafa loungeWebJun 25, 2015 · CLINICAL TRIALS AND OBSERVATIONS June 25, 2015 A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Clinical Trials & Observations Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus … ump faculty of computingWebApr 10, 2024 · The antibody, innate cell engager AFM13, acts as a bridge between the two cell types, helping the natural killer cells more effectively fight the cancer. Prior studies with AFM13 showed preliminary efficacy in clinical trials of patients with Hodgkin lymphoma, T-cell lymphoma, and peripheral T-cell lymphoma. ump gentillyWebMay 13, 2024 · These results led to the launch of a Phase I clinical trial to evaluate the combination of cord blood-derived NK cells (cbNK cells) with AFM13 as an experimental cell-based immunotherapy in ... umpf agencyWebApr 10, 2024 · AFM13, a bispecific tetravalent ICE® molecule, is designed for high affinity binding, both to CD16A on NK cells and macrophages, and to CD30 on lymphoma cells. … umphakathi design studio pty ltdWebDec 7, 2024 · This updated analysis of the AFM13 monotherapy study in patients with relapsed or refractory CD30-positive lymphoma with cutaneous presentation showed an Objective Response Rate (ORR) of 42 percent (6/14) and demonstrated clinical activity after brentuximab vedotin failure in two of four patients. umphafa berg toursWebAug 26, 2013 · In August 2013, LLS began its first European partnership with Affimed that supported two clinical trials for Hodgkin lymphoma (HL) patients. Expanding upon the initial work supported by LLS TAP, Affimed is currently enrolling "Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive … ump format thesis